DDAH1 and cancer: Pending the results of animal studies, the use of DDAH1 inhibitors, alone or in combination with traditional anti-angiogenic therapies such as anti-VEGF drugs, might represent a novel strategy to suppress both angiogenesis and VM, key factors in early cancer development and dissemination.